Facebook CEO’s Donation a Boon to Basic Science

But can $3 billion dollars meet the lofty goals of the Chan Zuckerberg Initiative?

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, JERICHOThe Chan Zuckerberg Initiative (CZI), a foundation launched by Facebook CEO Mark Zuckerberg and his wife, Priscilla Chan, aims to stop all diseases over the next century, and do it with just a tenth of the money the National Institutes of Health (NIH) spends annually. The centerpiece of the initiative will be a new facility in San Francisco devoted to creating a molecular catalog of cell types in the body and developing better responses to infectious disease, ScienceInsider reported.

The unveiling of the initiative this week (September 21) was met with a fair amount of skepticism. Popular Science pointed out that the NIH and pharmaceutical companies spend 22 times as much in one year as CZI will over a decade. “None of this is to say that we shouldn’t applaud such a large financial commitment to research,” the article added. “Maybe the Chan Zuckerberg Initiative will prove its critics wrong and provide the kind of innovation that the research community needs.”

What is particularly welcome to the life science community is the long view of CZI (100 years to accomplish its goals). “CZI plans to make it possible for large groups of scientists to focus on riskier projects that won't necessarily yield results for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies